No Way To Go But Grow: J&J Outlines Plans To Become A $60bn Pharma In 2025
Executive Summary
Management outlined its growth strategy to investors, highlighting plans to file 14 novel drugs with more than $1bn in peak sales by 2025.
You may also be interested in...
In Pfizer, J&J’s Innovation Centers, Incubators Lie Paths To Indian Innovation
Executives from J&J, Pfizer and Johns Hopkins share ideas on driving Indian biopharma innovation via innovation centers and incubators set up in association with academic institutions. On the other side of the table, Indian academia highlights the need for industry participation in skill building and the perils of ‘targeted thinking’
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the prospects and plans for J&J’s pharma and oncology business; China looks more inward under new policies; an important US approval for Takeda; and Moderna’s co-founder shares tips on innovation.
J&J's Next Immunology Act Centers On Nipocalimab For Autoantibody-Driven Diseases
The company has ramped up a broad R&D program for the FcRn inhibitor in 11 autoantibody-driven disease areas.